OpenFDA + PubChem + ClinicalTrials.gov Integration

FDA Detox Medications & Clinical Research Encyclopedia

Official US Food & Drug Administration (FDA) monographs, PubChem chemical pharmacology profiles, and active ClinicalTrials.gov research studies for addiction recovery and 24/7 medical detox.

FDA-Approved MAT & Detox Medications

Partial Opioid Agonist / MAT

Buprenorphine / Naloxone

FDA Approved (2002)

Brand Names: Suboxone, Zubsolv, Sublocade

FDA Indication:

Maintenance treatment of opioid dependence as part of a complete treatment plan including counseling and psychosocial support.

Receptor Mechanism: Partial agonist at the mu-opioid receptor and antagonist at the kappa-opioid receptor.

🚨 FDA Boxed Warning: WARNING: RISK OF SERIOUS HARM OR DEATH WITH ACCIDENTAL INGESTION; ADDICTION, ABUSE, AND MISUSE.

Package NDCs:54868-5256-012496-1208-10093-5720-56

OpenFDA API SynchronizedFind MAT Centers Offering Suboxone

Full Opioid Agonist / OTP

Methadone Hydrochloride

FDA Approved (1947)

Brand Names: Methadose, Dolophine

FDA Indication:

Detoxification treatment of opioid addiction and maintenance treatment of opioid dependence in certified Opioid Treatment Programs (OTP).

Receptor Mechanism: Full agonist at the mu-opioid receptor and NMDA receptor antagonist.

🚨 FDA Boxed Warning: WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; QT PROLONGATION.

Package NDCs:0054-3556-630054-4571-25

OpenFDA API SynchronizedFind MAT Centers Offering Methadose

Opioid Receptor Antagonist

Naltrexone Extended-Release

FDA Approved (1984 (Oral) / 2006 (Vivitrol Injectable))

Brand Names: Vivitrol, ReVia

FDA Indication:

Prevention of relapse to opioid dependence following opioid detoxification, and treatment of alcohol dependence.

Receptor Mechanism: Competitive antagonist at mu-opioid receptors, blocking euphoric effects of opioids and alcohol.

🚨 FDA Boxed Warning: WARNING: RISK OF HEPATOTOXICITY AT EXCESSIVE DOSES; OPIOID OVERDOSE RISK IF OPIOID BLOCK IS OVERRIDDEN.

Package NDCs:65757-300-010056-0079-01

OpenFDA API SynchronizedFind MAT Centers Offering Vivitrol

Opioid Antagonist / Emergency Reversal

Naloxone Hydrochloride

FDA Approved (1971 (FDA Over-The-Counter Approved 2023))

Brand Names: Narcan, Kloxxado, Zimhi

FDA Indication:

Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression.

Receptor Mechanism: Pure opioid antagonist that competes for and displaces opioids at mu-opioid receptor sites.

Package NDCs:69547-353-0270518-2450-0

OpenFDA API SynchronizedFind MAT Centers Offering Narcan

GABA Modulator / Glutamate Receptor Antagonist

Acamprosate Calcium

FDA Approved (2004)

Brand Names: Campral

FDA Indication:

Maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

Receptor Mechanism: Restores glutamate and GABA balance in the central nervous system altered by chronic alcohol exposure.

Package NDCs:0456-3200-01

OpenFDA API SynchronizedFind MAT Centers Offering Campral

Alcohol Dehydrogenase Inhibitor / Aversion Agent

Disulfiram

FDA Approved (1951)

Brand Names: Antabuse

FDA Indication:

Aid in the management of selected recovery patients who want to remain in a state of enforced sobriety from alcohol.

Receptor Mechanism: Inhibits aldehyde dehydrogenase (ALDH), leading to toxic accumulation of acetaldehyde upon alcohol consumption.

🚨 FDA Boxed Warning: WARNING: DISULFIRAM SHOULD NEVER BE ADMINISTERED TO AN INDIVIDUAL WHEN THEY ARE IN A STATE OF ALCOHOL INTOXICATION.

Package NDCs:0054-0065-25

OpenFDA API SynchronizedFind MAT Centers Offering Antabuse

MAT & Detox Centers Geo-Map

FDA-Approved Medication Assisted Treatment (MAT) Centers

Balanced 50-State coverage with municipal pin markers across all US regions

Filter Municipality:

Active US Clinical Research Trials (ClinicalTrials.gov APIv2)

Live interventional studies currently recruiting patients for addiction and detox research

NCT04366531RECRUITING (NA)

Successful Transitions and Reintegration Tools for Veterans (START-VETS)

This study will develop prison reentry materials for Veterans leaving prison.

Sponsor: VA Office of Research and Development

View Study on ClinicalTrials.gov

NCT05897099RECRUITING (NA)

Comprehensive HIV and Harm Prevention Via Telehealth

The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.

Sponsor: University of Miami

View Study on ClinicalTrials.gov

NCT06371404RECRUITING (PHASE_3)

Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat

The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurrent PTSD and AUD with control groups. While there are a large number of studies conducted in preclinical stress and addiction models, these findings have not been translated to people living with these disorders. This study will examine relationships between HDAC6 and clinical variables of interest. Findings could direct treatment development.

Sponsor: Yale University

View Study on ClinicalTrials.gov

NCT06379984RECRUITING (PHASE2)

Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use

The goal of this clinical trial is to learn if buprenorphine can be started for opioid use disorder with fentanyl use without requiring or precipitating opioid withdrawal. To be eligible, participants must have moderate or severe opioid use disorder and must have fentanyl detected on a urine drug test. Participants will be admitted to a monitored research unit for the trial. They will be randomized to start buprenorphine with either standard initiation or with a new approach called rapid outpatient low-dose initiation (ROLDI). For standard initiation, participants will be instructed to arrive to the unit with at least 8 hours since last fentanyl use. Once they have at least moderately severe opioid withdrawal (Clinical Opiate Withdrawal Scale \[COWS\] 11 or higher), participants will receive 2 mg, 2 mg, 4 mg, and then 8 mg sublingual buprenorphine, with doses every 2 hours. They will then continue 8 mg twice daily (or up to three times daily). This is the current standard of care. For ROLDI, participants will not be required to have a period abstinence, they will have no or minimal withdrawal (COWS 4 or less) when starting buprenorphine, and participants will take 0.5, 0.5, 0.5, 0.5, 2, 16 mg with doses scheduled every 2 hours. They will then continue 8mg twice daily (or up to three times daily). The main aim of this clinical trial is to assess whether ROLDI is safe, feasible, acceptable to patients, and worthwhile to study in a larger trial. The secondary aim is to describe fentanyl and norfentanyl pharmacokinetics (that is to say, fentanyl and norfentanyl concentration in blood and urine) during early abstinence to understand why some people using fentanyl develop precipitated withdrawal with standard initiation.

Sponsor: University of Pennsylvania

View Study on ClinicalTrials.gov

50-State Geographic Directory